Breaking News, Collaborations & Alliances

BostonGene, ImmunoGenesis Partner to Accelerate Development of Immune Checkpoint Inhibitor

ImmunoGenesis’ lead program, IMGS-001, is being studied in a Phase Ia/b trial in patients with solid tumors.

Author Image

By: Patrick Lavery

Content Marketing Editor

BostonGene, developer of a tumor and immune biology AI model, and ImmunoGenesis, a clinical-stage biotechnology company, announced a strategic partnership. The collaboration between the two companies spurs acceleration of clinical development for ImmunoGenesis’ lead program, IMGS-001. To explain further, this is a cytotoxic immune checkpoint inhibitor targeting programmed death-ligands 1 and 2 (PD-L1, PD-L2 respectively). Prior to this announcement, IMGS-001’s safety and efficacy were the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters